You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮製藥-B(01672.HK)口服小分子候選藥物有望成為治療新冠有效藥物
阿思達克 04-19 16:45
歌禮製藥-B(01672.HK)公布,其口服小分子候選藥物ASC11(3CLpro抑制劑)有望成為治療新冠肺炎的有效藥物。 抗新冠病毒細胞實驗顯示,ASC11的抗病毒活性(EC90)為奈瑪特韋的31倍(155/5),S-217622的120倍(600/5),PBI-0451的16倍(78/5)以及EDP-235的7倍(33/5)。而ASC11對新冠病毒不同的變異株均保持活性。 公司預期,在今年下半年提交ASC11臨床試驗申請,年底前完成在健康受試者中的I期臨床試驗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account